# Harmony Biosciences Pre-Announces Record Q2 2026 Revenue and CFO Departure

> news · REPORTED · 2026-07-16

Harmony Biosciences pre-announced record Q2 2026 quarterly revenue and reiterated full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion on the strength of continued WAKIX demand. Simultaneously, the company announced that CFO Glenn Reicin stepped down effective July 16, 2026.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing and marketing therapies for rare neurological diseases, primarily sleep-wake disorders such as narcolepsy and idiopathic hypersomnia, via its lead product WAKIX (pitolisant).

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://www.businesswire.com/news/home/20260716586168/en/Harmony-Biosciences-Preannounces-Record-Quarterly-Revenue-for-Q2-2026-Reaffirms-Full-Year-2026-Revenue-Guidance-and-Announces-CFO-Transition

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.